FDI in pharma and related implications of COVID-19
Arvind Sharma, Partner - M&A and General Corporate, Shardul Amarchand Mangaldas & Co states that the pharma sector is well…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
API
DoP to finalise guidelines to select locations of three bulk drug parks and four med devices parks:…
Govt of Punjab shows interest in extending support for the development of bulk drugs park in the State
Local API production in India for COVID-19 repurposed drugs may offer competitive advantage:…
The advantages will be in terms of supply and price for the formulations manufactured in India, be it remdesivir, favipiravir or…
Pharma industry requests time-bound amendments in DPCO 2013
The industry specifically appealed for amendments in Para 13 (2) and Para 15 (6) of DPCO 2013 to overcome the challenge of surging…
CDSCO to assess issues in the procurement and prices of APIs
This step is being taken by the authorities after media reports and representation by different pharma associations raise concerns…
Hydroxychloroquine consignment from India arrives in the US
The US has bought more than 29 million doses of hydroxychloroquine for COVID-19 patients
China’s recovery from COVID-19 should not tempt us to take the easy way out again
One silver lining of the COVID-19 infection is that policy decisions have been fast tracked
Government asks MoEFCC to expedite clearance of API/intermediates
It is an interim measure taken by the central government to ensure that all necessary projects or activities in respect of bulk…
C2 PHARMA opens research access to safety stock of Digoxin API for use in potential COVID-19…
Digoxin is extracted from the digitalis lanata plant. Due to the structure of the ingredient, it cannot be manufactured…
Industry players applaud govt’s move to boost manufacturing of APIs, med devices
The approved scheme will promote bulk drug parks for financing common infrastructure facilities in three bulk drug parks with a…